Genocea Biosciences (GNCA) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Genocea Provides Corporate Update, Including First-Quarter 2019 Financial Results
April 30, 2019 8:02 AM EDTCompany anticipates presenting first GEN-009 immunogenicity data at ASCO 2019
Conference call today at 9:00 am ET
CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today reported its operating and financial results for the first quarter ended March 31, 2019.
As we... More
